EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor

Feng Lin iD, Winghan Jacqueline Kwong, Irene Pan, Xin Ye iD, Dong Dai, William Tap

The Oncologist · 2024

DOI: 10.1093/oncolo/oyad282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Feng Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Outcomes Research, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA. Hauptthemen laut MEDLINE: Giant Cell Tumor of Tendon Sheath, Pyrroles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pexidartinib (Turalio) is the only systemic therapy approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant-cell tumor (TGCT) associated with severe morbidity or functional limitations, and not amenable to improvement with surgery. This study assessed patient-reported treatment experiences and symptom improvement among patients receiving pexidartinib.

Methods

A cross-sectional, web-based survey collected data on demographics, disease history, pexidartinib dosing, and symptoms before and after pexidartinib use.

Results

Of 288 patients enrolled in the Turalio REMS program in May 2021, 83 completed the survey: mean age was 44.2 years, 62.7% were female, and most common tumor sites were in knee (61%) and ankle (12%). Mean initial dose was 622 mg/day: 29 patients reported reduction from initial dose and 8 had dose reduction after titrating up to a higher dose. At the time of survey completion, median time on pexidartinib was 6.0 months; 22 (26.5%) patients discontinued pexidartinib due to physician suggestion, abnormal laboratory results, side effect, or symptom improvement. Compared with before pexidartinib initiation, most patients reported improvement in overall TGCT symptom (78.3%) and physical function (77.2%) during pexidartinib treatment. Significant improvement was reported during pexidartinib treatment in worst stiffness numeric rating scale (NRS) (3.0 vs. 6.2, P < .05) and worst pain NRS (2.7 vs. 5.7, P < .05).

Conclusion

Findings from this cross-sectional survey confirmed the benefit of pexidartinib in improving symptoms and functional outcomes among patients with symptomatic TGCTs from the patients’ perspective. Future research is warranted to examine the long-term benefit and risk of pexidartinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell Tumor of Tendon SheathPyrrolesAdultHumansFemaleMaleCross-Sectional StudiesAminopyridinesPatient Outcome Assessment

Stichwörter der Autor:innen

patient-reported outcomepexidartinibsymptom changetenosynovial giant-cell tumor

Substanzen

pexidartinibAminopyridinesPyrroles

Autor:innen und Institutionen

  • Health Economics and Outcomes Research, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.
  • Epidemiology and Real-World Evidence, United BioSource LLC, Blue Bell, PA, USA.
  • Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Feng Lin, Xin Ye

Förderung

  • NCI NIH HHS
  • Daiichi-Sankyo

Zitieren

APA

Lin, F., Jacqueline Kwong, W., Pan, I., Ye, X., Dai, D., & Tap, W. (2024). Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor. The Oncologist. https://doi.org/10.1093/oncolo/oyad282

Vancouver

Lin F, Jacqueline Kwong W, Pan I, Ye X, Dai D, Tap W. Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor. The Oncologist. 2024. doi:10.1093/oncolo/oyad282

BibTeX
@article{Lin2024,
  author = {Lin, Feng and Jacqueline Kwong, Winghan and Pan, Irene and Ye, Xin and Dai, Dong and Tap, William},
  title = {Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyad282}
}
Kostenlos starten →